Our findings are further supported by gene ontology analysis, showing reduced gliogenesis in individuals with amyloidosis without tau pathology, and increased gliogenesis in individuals with both amyloid and tau pathology [52]. The gene discussed is MAPT; the disease is amyloidosis.